168 related articles for article (PubMed ID: 37492625)
1. The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study.
Tommasi C; Scartabellati G; Giannarelli D; Giorgi U; Brighi N; Fornarini G; Rebuzzi SE; Puglisi S; Caffo O; Kinspergher S; Mennitto A; Cattrini C; Santoni M; Verzoni E; Rametta A; Stellato M; Malgeri A; Roviello G; Brunelli M; Buti S
Ther Adv Urol; 2023; 15():17562872231187216. PubMed ID: 37492625
[TBL] [Abstract][Full Text] [Related]
2. Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score.
Mazzaschi G; Lazzarin A; Santoni M; Trentini F; Giorgi U; Brighi N; Tommasi C; Puglisi S; Caffo O; Kinspergher S; Mennitto A; Cattrini C; Verzoni E; Rametta A; Stellato M; Malgeri A; Roviello G; Silini EM; Rescigno P; Rebuzzi SE; Fornarini G; Quaini F; Giudice GC; Banna GL; Buti S
Front Biosci (Elite Ed); 2023 Jul; 15(3):20. PubMed ID: 37743233
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib.
Bolzacchini E; Giordano M; Bertù L; Bregni M; Nigro O; Galli L; Antonuzzo A; Artale S; Barzaghi S; Danova M; Torchio M; Pinotti G; Dentali F
Tumori; 2022 Oct; 108(5):502-509. PubMed ID: 34296630
[TBL] [Abstract][Full Text] [Related]
4. External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations.
Maffezzoli M; Santoni M; Mazzaschi G; Rodella S; Lai E; Maruzzo M; Basso U; Bimbatti D; Iacovelli R; Anghelone A; Fiala O; Rebuzzi SE; Fornarini G; Lolli C; Massari F; Rosellini M; Mollica V; Nasso C; Acunzo A; Silini EM; Quaini F; De Filippo M; Brunelli M; Banna GL; Rescigno P; Signori A; Buti S
Clin Exp Metastasis; 2024 Apr; 41(2):117-129. PubMed ID: 38363410
[TBL] [Abstract][Full Text] [Related]
5. Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?
Corianò M; Giannarelli D; Scartabellati G; De Giorgi U; Brighi N; Fornarini G; Tommasi C; Giudice GC; Rebuzzi SE; Puglisi S; Caffo O; Kinspergher S; Mennitto A; Cattrini C; Santoni M; Verzoni E; Rametta A; Stellato M; Malgeri A; Roviello G; Brunelli M; Signori A; Banna GL; Buti S
Expert Rev Anticancer Ther; 2023 May; 23(5):545-554. PubMed ID: 37017710
[TBL] [Abstract][Full Text] [Related]
6. The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
Buti S; Tommasi C; Scartabellati G; De Giorgi U; Brighi N; Rebuzzi SE; Puglisi S; Caffo O; Kinspergher S; Mennitto A; Cattrini C; Santoni M; Verzoni E; Rametta A; Stellato M; Malgeri A; Roviello G; de Filippo M; Cortellini A; Bersanelli M
Anticancer Drugs; 2023 Jan; 34(1):178-186. PubMed ID: 36539370
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
Bourlon MT; Gao D; Trigero S; Clemons JE; Breaker K; Lam ET; Flaig TW
Cancer Med; 2016 Dec; 5(12):3386-3393. PubMed ID: 27758076
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.
Santoni M; Massari F; Bracarda S; Grande E; Matrana MR; Rizzo M; De Giorgi U; Basso U; Aurilio G; Incorvaia L; Martignetti A; Molina-Cerrillo J; Mollica V; Rizzo A; Battelli N
Eur Urol Focus; 2022 Nov; 8(6):1696-1702. PubMed ID: 35193819
[TBL] [Abstract][Full Text] [Related]
9. Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma.
Kucharz J; Giza A; Dumnicka P; Kuzniewski M; Kusnierz-Cabala B; Bryniarski P; Herman R; Zygulska AL; Krzemieniecki K
Med Oncol; 2016 Oct; 33(10):109. PubMed ID: 27573381
[TBL] [Abstract][Full Text] [Related]
10. Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment.
Kloth JSL; Hamberg P; Mendelaar PAJ; Dulfer RR; van der Holt B; Eechoute K; Wiemer EAC; Kruit WHJ; Sleijfer S; Mathijssen RHJ
Eur J Cancer; 2016 Mar; 56():101-106. PubMed ID: 26841094
[TBL] [Abstract][Full Text] [Related]
11. Preoperative red blood cell distribution width as an independent prognostic factor in metastatic renal cell carcinoma.
Wei Z; Zhang F; Ma X; He W; Gou X; Zhang X; Xie Y
Transl Oncol; 2022 Sep; 23():101486. PubMed ID: 35839619
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study.
Iinuma K; Tomioka-Inagawa R; Kameyama K; Taniguchi T; Kawada K; Ishida T; Nagai S; Enomoto T; Ueda S; Kawase M; Takeuchi S; Kawase K; Kato D; Takai M; Nakane K; Koie T
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551927
[TBL] [Abstract][Full Text] [Related]
13. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors.
Roviello G; Catalano M; De Giorgi U; Maruzzo M; Buti S; Gambale E; Procopio G; Ottanelli C; Caliman E; Isella L; Sepe P; Brighi N; Santoni M; Galli L; Conca R; Doni L; Antonuzzo L
Front Oncol; 2022; 12():918413. PubMed ID: 36052244
[TBL] [Abstract][Full Text] [Related]
15. Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib.
Hidalgo-Ríos S; Carrillo-García J; Moura DS; Stacchiotti S; López-Pousa A; Redondo A; Italiano A; Gutiérrez A; Grignani G; Hindi N; López-Guerrero JA; Muro XGD; Trufero JM; Palmerini E; García AS; Bernabeu D; Le Cesne A; Casali PG; Blay JY; Cruz Jurado J; Martin-Broto J
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077723
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of preoperative anemia, abnormal mean corpuscular volume and red cell distribution width among surgical patients in Singapore, and their influence on one year mortality.
Sim YE; Wee HE; Ang AL; Ranjakunalan N; Ong BC; Abdullah HR
PLoS One; 2017; 12(8):e0182543. PubMed ID: 28777814
[TBL] [Abstract][Full Text] [Related]
17. High Red Cell Distribution Width Independently Predicts Adverse Survival in Patients with Newly Diagnosed Skull Base Chordoma.
Li M; Shen Y; Xiong Y; Bai J; Wang S; Li C; Zhang Y
Onco Targets Ther; 2021; 14():5435-5445. PubMed ID: 34924760
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study.
Chen J; Ye W; Jiang W; Li X; Liu R; Lin B; Xiang J; Tian W; Bai J; Zuo T; Lin B; Guo Y; Zheng S
Transl Androl Urol; 2021 Mar; 10(3):1321-1331. PubMed ID: 33850766
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study.
Benekli M; Gumus M; Ozkan M; Dane F; Elkiran ET; Cicin I; Sevinc A; Aliustaoglu M; Isikdogan A; Meydan N; Oksuzoglu B; Ozyilkan O; Artac M; Ozdemir F; Kilickap S
J Oncol Pharm Pract; 2021 Oct; 27(7):1623-1630. PubMed ID: 33050804
[TBL] [Abstract][Full Text] [Related]
20. The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy.
Aktepe OH; Guven DC; Sahin TK; Yildirim HC; Celikten B; Yeter HH; Yuce D; Dizdar O; Erman M
Nutr Cancer; 2021; 73(10):1957-1963. PubMed ID: 33491495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
